JP2010522208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522208A5 JP2010522208A5 JP2009554753A JP2009554753A JP2010522208A5 JP 2010522208 A5 JP2010522208 A5 JP 2010522208A5 JP 2009554753 A JP2009554753 A JP 2009554753A JP 2009554753 A JP2009554753 A JP 2009554753A JP 2010522208 A5 JP2010522208 A5 JP 2010522208A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- liquid formulation
- imc
- polysorbate
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91974407P | 2007-03-22 | 2007-03-22 | |
| PCT/US2008/057718 WO2008116103A2 (en) | 2007-03-22 | 2008-03-20 | Stable antibody formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010522208A JP2010522208A (ja) | 2010-07-01 |
| JP2010522208A5 true JP2010522208A5 (https=) | 2011-04-28 |
Family
ID=39766776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554753A Pending JP2010522208A (ja) | 2007-03-22 | 2008-03-20 | 安定な抗体処方物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100260766A1 (https=) |
| EP (1) | EP2136839A4 (https=) |
| JP (1) | JP2010522208A (https=) |
| KR (1) | KR20090113340A (https=) |
| CN (1) | CN101668540A (https=) |
| AU (1) | AU2008228823A1 (https=) |
| BR (1) | BRPI0809112A2 (https=) |
| CA (1) | CA2681743A1 (https=) |
| CR (1) | CR11005A (https=) |
| DO (1) | DOP2009000222A (https=) |
| EA (1) | EA200970880A1 (https=) |
| EC (1) | ECSP099642A (https=) |
| IL (1) | IL200321A0 (https=) |
| MX (1) | MX2009010179A (https=) |
| TN (1) | TN2009000382A1 (https=) |
| UA (1) | UA96473C2 (https=) |
| WO (1) | WO2008116103A2 (https=) |
| ZA (1) | ZA200905636B (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| TW200838559A (en) * | 2006-11-29 | 2008-10-01 | Imclone Systems Inc | Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| EP2362767B1 (en) | 2008-10-29 | 2017-12-06 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
| BRPI0919879A2 (pt) | 2008-10-29 | 2016-02-16 | Wyeth Llc | métodos para purificação de moléculas de ligação a antígeno de domínio único |
| JP5933975B2 (ja) * | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| NZ592151A (en) | 2008-12-12 | 2012-10-26 | Boehringer Ingelheim Int | Anti-igf antibodies |
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| CA2810731A1 (en) | 2010-09-17 | 2012-03-22 | Baxter International Inc. | Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral ph |
| MX362591B (es) | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| EA201992617A1 (ru) * | 2011-10-26 | 2020-03-10 | Амген Инк. | Способы уменьшения или устранения модификации и разложения белка, обусловленных воздействием уф-излучения |
| US8609820B2 (en) | 2011-10-28 | 2013-12-17 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| NZ629296A (en) | 2012-01-27 | 2016-06-24 | Prothena Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
| AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| AR094821A1 (es) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| JP2016505601A (ja) | 2012-12-26 | 2016-02-25 | ウォックハート リミテッド | 医薬組成物 |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| JP6744856B2 (ja) | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | α−シヌクレインを認識する抗体を含む血液脳関門シャトル |
| AU2015358615B2 (en) | 2014-12-04 | 2021-08-05 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute myeloid leukemia |
| SG11201705484WA (en) * | 2015-02-09 | 2017-08-30 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| DK3827845T3 (da) | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| JP6992262B2 (ja) * | 2016-03-31 | 2022-02-15 | 東ソー株式会社 | 変性抗体測定試薬の製造方法 |
| JP2019527678A (ja) | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療 |
| WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| JP2021502961A (ja) | 2017-10-31 | 2021-02-04 | ヤンセン バイオテツク，インコーポレーテツド | 高リスク多発性骨髄腫の治療方法 |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| CN112206320B (zh) * | 2019-07-12 | 2025-02-25 | 鲁南制药集团股份有限公司 | 一种cd47单克隆抗体冻干粉制剂及其制备工艺 |
| AU2021278562A1 (en) | 2020-05-29 | 2022-12-01 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing formulation |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| EP1400536A1 (en) * | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| AU2002213441B2 (en) * | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| PH12012502440A1 (en) * | 2001-06-26 | 2013-06-17 | Amgen Inc | Antibodies to opgl |
| CA2454587C (en) * | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| AU2003211990A1 (en) * | 2002-02-14 | 2003-09-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing solution pharmaceuticals |
| AU2004212344B2 (en) * | 2003-02-13 | 2009-05-07 | Pfizer Products Inc. | Uses of anti-insulin-like growth factor I receptor antibodies |
| WO2005016970A2 (en) * | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| AR046071A1 (es) * | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| MXPA06001634A (es) * | 2003-08-13 | 2006-04-28 | Pfizer Prod Inc | Anticuerpos humanos modificados igf-1r. |
| AU2006247039B2 (en) * | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| KR20080019249A (ko) * | 2005-06-15 | 2008-03-03 | 쉐링 코포레이션 | 안정한 항체 제형 |
| WO2007110339A1 (en) * | 2006-03-28 | 2007-10-04 | F. Hoffmann-La Roche Ag | Anti-igf-1r human monoclonal antibody formulation |
-
2008
- 2008-03-20 AU AU2008228823A patent/AU2008228823A1/en not_active Abandoned
- 2008-03-20 EA EA200970880A patent/EA200970880A1/ru unknown
- 2008-03-20 CA CA002681743A patent/CA2681743A1/en not_active Abandoned
- 2008-03-20 US US12/528,882 patent/US20100260766A1/en not_active Abandoned
- 2008-03-20 MX MX2009010179A patent/MX2009010179A/es not_active Application Discontinuation
- 2008-03-20 EP EP08744136A patent/EP2136839A4/en not_active Withdrawn
- 2008-03-20 KR KR1020097019642A patent/KR20090113340A/ko not_active Abandoned
- 2008-03-20 WO PCT/US2008/057718 patent/WO2008116103A2/en not_active Ceased
- 2008-03-20 BR BRPI0809112-9A patent/BRPI0809112A2/pt not_active IP Right Cessation
- 2008-03-20 JP JP2009554753A patent/JP2010522208A/ja active Pending
- 2008-03-20 UA UAA200909552A patent/UA96473C2/ru unknown
- 2008-03-20 CN CN200880009446A patent/CN101668540A/zh active Pending
-
2009
- 2009-08-10 IL IL200321A patent/IL200321A0/en unknown
- 2009-08-13 ZA ZA200905636A patent/ZA200905636B/xx unknown
- 2009-08-28 CR CR11005A patent/CR11005A/es not_active Application Discontinuation
- 2009-09-18 TN TNP2009000382A patent/TN2009000382A1/fr unknown
- 2009-09-18 DO DO2009000222A patent/DOP2009000222A/es unknown
- 2009-09-21 EC EC2009009642A patent/ECSP099642A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010522208A5 (https=) | ||
| JP2010529999A5 (https=) | ||
| JP2011088913A5 (https=) | ||
| AR124140A2 (es) | Formulaciones de anticuerpos | |
| JP2007262090A5 (https=) | ||
| NZ595526A (en) | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant | |
| JP2016513069A5 (https=) | ||
| UA96473C2 (ru) | Жидкая стойкая композиция, которая содержит антитело imc-а12 | |
| RU2009148286A (ru) | Жидкая фармацевтическая композиция ботулинического токсина | |
| JP2006517944A5 (https=) | ||
| JP2009521520A5 (https=) | ||
| JP2007522094A5 (https=) | ||
| FI4374878T3 (fi) | Karbetosiinia käsittävä farmaseuttinen koostumus | |
| JP2012515184A5 (https=) | ||
| JP2014520852A5 (https=) | ||
| JP2008531742A5 (https=) | ||
| JP2013510169A5 (https=) | ||
| JP2005527551A5 (https=) | ||
| CO6220900A2 (es) | Forma dosificadora novedosa | |
| CY1112917T1 (el) | Υγρες στοματικες συνθεσεις | |
| PE20130374A1 (es) | Composicion farmaceutica que comprende ibuprofeno | |
| JP2011068692A5 (https=) | ||
| JP2009523791A5 (https=) | ||
| RU2010104395A (ru) | Пероральные фармацевтические растворы, содержащие телбивудин | |
| JP2010540461A5 (https=) |